Global Relapsed Acute Myeloid Leukemia Drug Market Professional Survey Report 2019

Table of Contents

Executive Summary

1 Industry Overview of Relapsed Acute Myeloid Leukemia Drug

• 1.1 Definition of Relapsed Acute Myeloid Leukemia Drug
• 1.2 Relapsed Acute Myeloid Leukemia Drug Segment by Type
  • 1.2.1 Global Relapsed Acute Myeloid Leukemia Drug Production Growth Rate Comparison by Types (2014-2025)
  • 1.2.2 aNK Program
  • 1.2.3 AT-9283
  • 1.2.4 BI-836858
  • 1.2.5 binimetinib
  • 1.2.6 BL-8040
  • 1.2.7 Others
• 1.3 Relapsed Acute Myeloid Leukemia Drug Segment by Applications
  • 1.3.1 Global Relapsed Acute Myeloid Leukemia Drug Consumption Comparison by Applications (2014-2025)
  • 1.3.2 Clinic
  • 1.3.3 Hospital
  • 1.3.4 Others
• 1.4 Global Relapsed Acute Myeloid Leukemia Drug Overall Market
  • 1.4.1 Global Relapsed Acute Myeloid Leukemia Drug Revenue (2014-2025)
  • 1.4.2 Global Relapsed Acute Myeloid Leukemia Drug Production (2014-2025)
  • 1.4.3 North America Relapsed Acute Myeloid Leukemia Drug Status and Prospect (2014-2025)
  • 1.4.4 Europe Relapsed Acute Myeloid Leukemia Drug Status and Prospect (2014-2025)
  • 1.4.5 China Relapsed Acute Myeloid Leukemia Drug Status and Prospect (2014-2025)
  • 1.4.6 Japan Relapsed Acute Myeloid Leukemia Drug Status and Prospect (2014-2025)
  • 1.4.7 Southeast Asia Relapsed Acute Myeloid Leukemia Drug Status and Prospect (2014-2025)
  • 1.4.8 India Relapsed Acute Myeloid Leukemia Drug Status and Prospect (2014-2025)

2 Manufacturing Cost Structure Analysis

• 2.1 Raw Material and Suppliers
• 2.2 Manufacturing Cost Structure Analysis of Relapsed Acute Myeloid Leukemia Drug
• 2.3 Manufacturing Process Analysis of Relapsed Acute Myeloid Leukemia Drug
• 2.4 Industry Chain Structure of Relapsed Acute Myeloid Leukemia Drug

3 Development and Manufacturing Plants Analysis of Relapsed Acute Myeloid Leukemia Drug

• 3.1 Capacity and Commercial Production Date
• 3.2 Global Relapsed Acute Myeloid Leukemia Drug Manufacturing Plants Distribution
• 3.3 Major Manufacturers Technology Source and Market Position of Relapsed Acute Myeloid Leukemia Drug
• 3.4 Recent Development and Expansion Plans

4 Key Figures of Major Manufacturers

• 4.1 Relapsed Acute Myeloid Leukemia Drug Production and Capacity Analysis
• 4.2 Relapsed Acute Myeloid Leukemia Drug Revenue Analysis
• 4.3 Relapsed Acute Myeloid Leukemia Drug Price Analysis
• 4.4 Market Concentration Degree

5 Relapsed Acute Myeloid Leukemia Drug Regional Market Analysis

• 5.1 Relapsed Acute Myeloid Leukemia Drug Production by Regions
  • 5.1.1 Global Relapsed Acute Myeloid Leukemia Drug Production by Regions
  • 5.1.2 Global Relapsed Acute Myeloid Leukemia Drug Revenue by Regions
• 5.2 Relapsed Acute Myeloid Leukemia Drug Consumption by Regions
• 5.3 North America Relapsed Acute Myeloid Leukemia Drug Market Analysis
  • 5.3.1 North America Relapsed Acute Myeloid Leukemia Drug Production
  • 5.3.2 North America Relapsed Acute Myeloid Leukemia Drug Revenue
  • 5.3.3 Key Manufacturers in North America
  • 5.3.4 North America Relapsed Acute Myeloid Leukemia Drug Import and Export
• 5.4 Europe Relapsed Acute Myeloid Leukemia Drug Market Analysis
  • 5.4.1 Europe Relapsed Acute Myeloid Leukemia Drug Production
  • 5.4.2 Europe Relapsed Acute Myeloid Leukemia Drug Revenue
  • 5.4.3 Key Manufacturers in Europe
  • 5.4.4 Europe Relapsed Acute Myeloid Leukemia Drug Import and Export
• 5.5 China Relapsed Acute Myeloid Leukemia Drug Market Analysis
  • 5.5.1 China Relapsed Acute Myeloid Leukemia Drug Production
  • 5.5.2 China Relapsed Acute Myeloid Leukemia Drug Revenue
  • 5.5.3 Key Manufacturers in China
  • 5.5.4 China Relapsed Acute Myeloid Leukemia Drug Import and Export
• 5.6 Japan Relapsed Acute Myeloid Leukemia Drug Market Analysis
  • 5.6.1 Japan Relapsed Acute Myeloid Leukemia Drug Production
  • 5.6.2 Japan Relapsed Acute Myeloid Leukemia Drug Revenue
  • 5.6.3 Key Manufacturers in Japan
  • 5.6.4 Japan Relapsed Acute Myeloid Leukemia Drug Import and Export
• 5.7 Southeast Asia Relapsed Acute Myeloid Leukemia Drug Market Analysis
  • 5.7.1 Southeast Asia Relapsed Acute Myeloid Leukemia Drug Production
  • 5.7.2 Southeast Asia Relapsed Acute Myeloid Leukemia Drug Revenue
  • 5.7.3 Key Manufacturers in Southeast Asia
  • 5.7.4 Southeast Asia Relapsed Acute Myeloid Leukemia Drug Import and Export
• 5.8 India Relapsed Acute Myeloid Leukemia Drug Market Analysis
  • 5.8.1 India Relapsed Acute Myeloid Leukemia Drug Production
  • 5.8.2 India Relapsed Acute Myeloid Leukemia Drug Revenue
  • 5.8.3 Key Manufacturers in India
  • 5.8.4 India Relapsed Acute Myeloid Leukemia Drug Import and Export

6 Relapsed Acute Myeloid Leukemia Drug Segment Market Analysis (by Type)

• 6.1 Global Relapsed Acute Myeloid Leukemia Drug Production by Type
• 6.2 Global Relapsed Acute Myeloid Leukemia Drug Revenue by Type
• 6.3 Relapsed Acute Myeloid Leukemia Drug Price by Type

7 Relapsed Acute Myeloid Leukemia Drug Segment Market Analysis (by Application)

• 7.1 Global Relapsed Acute Myeloid Leukemia Drug Consumption by Application
• 7.2 Global Relapsed Acute Myeloid Leukemia Drug Consumption Market Share by Application (2014-2019)

8 Relapsed Acute Myeloid Leukemia Drug Major Manufacturers Analysis

• 8.1 4SC AG
  • 8.1.1 4SC AG Relapsed Acute Myeloid Leukemia Drug Production Sites and Area Served
  • 8.1.2 4SC AG Product Introduction, Application and Specification
  • 8.1.3 4SC AG Relapsed Acute Myeloid Leukemia Drug Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
  • 8.1.4 Main Business and Markets Served
• 8.2 AbbVie Inc.
  • 8.2.1 AbbVie Inc. Relapsed Acute Myeloid Leukemia Drug Production Sites and Area Served
  • 8.2.2 AbbVie Inc. Product Introduction, Application and Specification
  • 8.2.3 AbbVie Inc. Relapsed Acute Myeloid Leukemia Drug Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
  • 8.2.4 Main Business and Markets Served
• 8.3 Actinium Pharmaceuticals, Inc.
  • 8.3.1 Actinium Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Production Sites and Area Served
  • 8.3.2 Actinium Pharmaceuticals, Inc. Product Introduction, Application and Specification
  • 8.3.3 Actinium Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
  • 8.3.4 Main Business and Markets Served
• 8.4 Agios Pharmaceuticals, Inc.
  • 8.4.1 Agios Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Production Sites and Area Served
  • 8.4.2 Agios Pharmaceuticals, Inc. Product Introduction, Application and Specification
  • 8.4.3 Agios Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
  • 8.4.4 Main Business and Markets Served
• 8.5 Amgen Inc.
  • 8.5.1 Amgen Inc. Relapsed Acute Myeloid Leukemia Drug Production Sites and Area Served
  • 8.5.2 Amgen Inc. Product Introduction, Application and Specification
  • 8.5.3 Amgen Inc. Relapsed Acute Myeloid Leukemia Drug Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
  • 8.5.4 Main Business and Markets Served
• 8.6 Arog Pharmaceuticals, Inc.
  • 8.6.1 Arog Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Production Sites and Area Served
  • 8.6.2 Arog Pharmaceuticals, Inc. Product Introduction, Application and Specification
  • 8.6.3 Arog Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
  • 8.6.4 Main Business and Markets Served
• 8.7 Array BioPharma Inc.
  • 8.7.1 Array BioPharma Inc. Relapsed Acute Myeloid Leukemia Drug Production Sites and Area Served
  • 8.7.2 Array BioPharma Inc. Product Introduction, Application and Specification
  • 8.7.3 Array BioPharma Inc. Relapsed Acute Myeloid Leukemia Drug Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
  • 8.7.4 Main Business and Markets Served
• 8.8 Astellas Pharma Inc.
  • 8.8.1 Astellas Pharma Inc. Relapsed Acute Myeloid Leukemia Drug Production Sites and Area Served
  • 8.8.2 Astellas Pharma Inc. Product Introduction, Application and Specification
  • 8.8.3 Astellas Pharma Inc. Relapsed Acute Myeloid Leukemia Drug Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
  • 8.8.4 Main Business and Markets Served
• 8.9 Astex Pharmaceuticals, Inc.
  • 8.9.1 Astex Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Production Sites and Area Served
  • 8.9.2 Astex Pharmaceuticals, Inc. Product Introduction, Application and Specification
  • 8.9.3 Astex Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
  • 8.9.4 Main Business and Markets Served
• 8.10 AstraZeneca Plc
  • 8.10.1 AstraZeneca Plc Relapsed Acute Myeloid Leukemia Drug Production Sites and Area Served
  • 8.10.2 AstraZeneca Plc Product Introduction, Application and Specification
  • 8.10.3 AstraZeneca Plc Relapsed Acute Myeloid Leukemia Drug Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
  • 8.10.4 Main Business and Markets Served
• 8.11 AVEO Pharmaceuticals, Inc.
• 8.12 BioLineRx, Ltd.
• 8.13 Boehringer Ingelheim GmbH
• 8.14 Boston Biomedical, Inc.
• 8.15 Bristol-Myers Squibb Company
• 8.16 Calithera Biosciences, Inc.
• 8.17 Celgene Corporation
• 8.18 Cornerstone Pharmaceuticals, Inc.
• 8.19 CTI BioPharma Corp.

9 Development Trend of Analysis of Relapsed Acute Myeloid Leukemia Drug Market

• 9.1 Global Relapsed Acute Myeloid Leukemia Drug Market Trend Analysis
  • 9.1.1 Global Relapsed Acute Myeloid Leukemia Drug Market Size (Volume and Value) Forecast 2019-2025
• 9.2 Relapsed Acute Myeloid Leukemia Drug Regional Market Trend
  • 9.2.1 North America Relapsed Acute Myeloid Leukemia Drug Forecast 2019-2025
  • 9.2.2 Europe Relapsed Acute Myeloid Leukemia Drug Forecast 2019-2025
  • 9.2.3 China Relapsed Acute Myeloid Leukemia Drug Forecast 2019-2025
  • 9.2.4 Japan Relapsed Acute Myeloid Leukemia Drug Forecast 2019-2025
  • 9.2.5 Southeast Asia Relapsed Acute Myeloid Leukemia Drug Forecast 2019-2025
  • 9.2.6 India Relapsed Acute Myeloid Leukemia Drug Forecast 2019-2025
• 9.3 Relapsed Acute Myeloid Leukemia Drug Market Trend (Product Type)
• 9.4 Relapsed Acute Myeloid Leukemia Drug Market Trend (Application)
• 10.1 Marketing Channel
  • 10.1.1 Direct Marketing
  • 10.1.2 Indirect Marketing
• 10.3 Relapsed Acute Myeloid Leukemia Drug Customers

11 Market Dynamics

• 11.1 Market Trends
• 11.2 Opportunities
• 11.3 Market Drivers
• 11.4 Challenges
• 11.5 Influence Factors

12 Conclusion

13 Appendix

• 13.1 Methodology/Research Approach
  • 13.1.1 Research Programs/Design
  • 13.1.2 Market Size Estimation
  • 13.1.3 Market Breakdown and Data Triangulation
• 13.2 Data Source
  • 13.2.1 Secondary Sources
  • 13.2.2 Primary Sources
• 13.3 Author List